Market Overview

Credit Suisse Takes Neutral Stance On Mednax, Says Buyout Value Reflected In Share Price

Share:
Credit Suisse Takes Neutral Stance On Mednax, Says Buyout Value Reflected In Share Price
Related MD
Earnings Scheduled For November 1, 2018
Leerink Upgrades Mednax On Margin Expansion, Share Gains And Valuation

MEDNAX, Inc. (NYSE: MD) has continued to pursue acquisitions to grow its radiology business segment, making the company a potential private equity target. The company's takeout value appears to be reflected inits valuation, limiting any compelling risk-reward opportunity, according to Credit Suisse.

The Analyst

A.J. Rice of Credit Suisse initiated coverage on Mednax with a Neutral rating and a $57 target price.

The Thesis

Mednax has consistently acquired 10-15 practices annually, primarily through the company’s Pediatrix business, Rice said in a Tuesday note. Since 2012, the company has shifted its focus to radiology and used its vRad teleradiology business as a selling point, the analyst said. 

“MD makes the case that vRad can be used in ways that benefit facility-based physicians financially and otherwise. For example, rather than having radiologists cover at night, vRad can provide coverage for those needs at lower utilization times," Rice said. 

Since December 2017, reports have pointed to takeout interest from private equity firms. In November, activist investor Elliott Management disclosed it had exposure to Mednax and announced plans to engage with the company’s board to discuss strategic options, according to Credit Suisse. 

The value of a potential takeout could already be reflected in Mednax's share price, the analyst said.

“Given the run-up that the shares have enjoyed since disclosure of Elliott’s involvement in November 2017, the current valuation does not, in our view, offer a compelling risk-reward opportunity.”

Price Action

At the time of publication, shares of MEDNAX were trading down 0.35 percent at $54.87. 

Related Links:

Benzinga's Top Upgrades, Downgrades For March 27, 2018

Elliott's Paul Singer Calls Cryptocurrencies A 'Brilliant Scam' 

Latest Ratings for MD

DateFirmActionFromTo
Nov 2018UBSInitiates Coverage OnSell
Nov 2018Credit SuisseMaintainsOutperformOutperform
Nov 2018BairdMaintainsNeutralNeutral

View More Analyst Ratings for MD
View the Latest Analyst Ratings

Posted-In: A.J. Rice Credit SuisseAnalyst Color Health Care Price Target Initiation Analyst Ratings General Best of Benzinga

 

Related Articles (MD)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
LXFTKeyBancDowngrades0.0
CPAImperial CapitalDowngrades68.0
PRMWImperial CapitalInitiates Coverage On18.0
TGTKeyBancInitiates Coverage On110.0
QCOMMorgan StanleyUpgrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

BB&T Should Trade At Premium To Other Large-Cap Banks, Says B Riley FBR

Mid-Afternoon Market Update: NASDAQ Down Over 100 Points; Invitae Shares Fall Following Announcement Of $50M Common Stock Offering